Indirect Treatment Comparison of Ustekinumab Versus Other Biologics in Moderate-to-Severe Crohnʼs Disease Patients Having Failed Anti-TNF Therapy: A 1-Year Treatment Sequence Analysis Including Delayed Responders

Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor

“…Three indirect comparisons and four network meta‐analyses of randomised controlled trials have compared ustekinumab to vedolizumab in CD patients, in anti‐TNF refractory patients. Among the indirect comparisons, two found no difference in induction 16,17 and maintenance treatment 16 ; while a third study found that ustekinumab was more efficient than vedolizumab in maintenance treatment 15 . Among the network meta‐analyses, two found no difference between ustekinumab and vedolizumab in induction 11,14 .…”

“…In this meta-analysis, the study by Townsend et al 20 indirect comparisons, two found no difference in induction 16,17 and maintenance treatment 16 ; while a third study found that ustekinumab was more efficient than vedolizumab in maintenance treatment. 15 Among the network meta-analyses, two found no difference between ustekinumab and vedolizumab in induction. 11,14 Two meta analyses were limited to maintenance therapy, and found no statistical difference between vedolizumab and ustekinumab.…”

“…Randomised placebo‐controlled trials have proven the efficacy of ustekinumab and of vedolizumab in anti‐TNF‐naïve and experienced CD patients, 9,10 but no head‐to‐head trial has compared these two drugs. Indirect comparisons and network meta‐analyses of randomised trials have led to conflicting conclusions 11‐17 . Recently, several observational studies have compared ustekinumab and vedolizumab, in patients with CD 18‐24 …”